Finanzen von Aktis Oncology Inc (AKTS)AKTSAktis Oncology Inc

Aktis Oncology Inc (AKTS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is RF Filters, accounting for 57.1% of total sales, equivalent to $3.34M. Another important revenue stream is Foundry Fabrication Services. Understanding this composition is critical for investors evaluating how AKTS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Aktis Oncology Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -853.99%, while the net margin is -713.48%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AKTS converts its operational activities into shareholder value.

In the context of the broader market, AKTS competes directly with industry leaders such as IMTX and HROW. With a market capitalization of $1.43B, it holds a significant position in the sector. When comparing efficiency, AKTS's gross margin of 100.00% stands against IMTX's 100.00% and HROW's 71.27%. Such benchmarking helps identify whether Aktis Oncology Inc is trading at a premium or discount relative to its financial performance.

Aktis Oncology has shown increasing total revenue, with Q2 2026 revenue at 3,384,000 USD compared to 1,447,000 USD in Q1 2025. However, it continues to report significant net losses, with Q2 2026 net income at -24,144,000 USD.